Belzutifan HIF-2α Inhibitor Pipeline — PatSnap Eureka
Belzutifan Pipeline Expansion: Phase 3 Data in RCC & VHL Disease
Merck's belzutifan (Welireg) is redefining the treatment landscape for clear cell renal cell carcinoma and VHL disease. Explore LITESPARK Phase 3 trial outcomes, combination strategies, and the competitive patent environment — powered by PatSnap Eureka.
How Belzutifan Targets HIF-2α in VHL-Driven Cancers
Belzutifan (MK-6482, brand name Welireg) is a potent, selective, and orally available HIF-2α inhibitor developed by Merck following its acquisition of Peloton Therapeutics. The drug acts by binding to the PAS-B domain of HIF-2α, disrupting its heterodimerization with ARNT (HIF-1β) — the obligate partner required for transcriptional activity.
Under normal physiology, the VHL protein (pVHL) acts as the substrate recognition subunit of an E3 ubiquitin ligase complex that polyubiquitinates hydroxylated HIF-α subunits, targeting them for proteasomal degradation. Loss-of-function mutations in VHL — whether germline (VHL disease) or somatic (sporadic ccRCC) — result in constitutive HIF-2α stabilization and transcriptional activation of hypoxia-response genes including VEGF, PDGF, EPO, TGF-α, GLUT1, and cyclin D1.
By selectively disrupting HIF-2α/ARNT heterodimerization, belzutifan provides a mechanistically rational therapeutic strategy for VHL-driven malignancies. The drug received its first global approval on 13 August 2021 in the USA for adults with VHL disease-associated RCC, CNS hemangioblastomas, or pancreatic neuroendocrine tumours (pNETs) who do not require immediate surgery — marking the first approved HIF-2α inhibitor. Track the evolving IP landscape around this mechanism via PatSnap's patent analytics platform.
The LITESPARK Trial Portfolio: From VHL Disease to First-Line ccRCC
Belzutifan's clinical development spans multiple LITESPARK studies, progressively expanding from VHL disease to broader advanced ccRCC indications — both as monotherapy and in combination regimens.
LITESPARK-004: Foundation of FDA Approval
The pivotal phase 2 trial (NCT03401788) enrolled 61 patients with VHL disease-associated renal cell carcinoma. Belzutifan at 120 mg once daily demonstrated a confirmed ORR of 49% with a median duration of response that had not been reached at data cutoff. The estimated probability of maintaining response at 24 months was 82%, indicating highly durable responses. The study also assessed activity in CNS hemangioblastomas and pancreatic neuroendocrine tumours, forming the basis for belzutifan's FDA approval.
ORR 49% · 24-month response rate 82%LITESPARK-005: Belzutifan vs Everolimus
This phase 3 randomised study evaluated belzutifan versus everolimus in 746 patients with advanced ccRCC who previously received anti-PD-1/PD-L1 therapy and a VEGF-targeted agent. Belzutifan demonstrated a confirmed ORR of 21.9% versus 3.5% for everolimus (p<0.0001). Median PFS was 5.6 months for both arms. Overall survival data were immature, but the hazard ratio favoured belzutifan (HR=0.88; 95% CI: 0.73–1.06), supporting belzutifan as a new treatment option for previously treated advanced ccRCC.
ORR 21.9% vs 3.5% · HR OS 0.88LITESPARK-003: Triplet Combination Data
This phase 1b/2 dose-escalation/expansion study evaluated belzutifan in combination with lenvatinib and pembrolizumab in advanced ccRCC. The triplet combination achieved an ORR of 65% in first-line ccRCC patients (n=40) with a median PFS of 24.0 months. In previously treated patients, ORR was 48% (n=25). The triplet showed promising efficacy with manageable tolerability, providing the rationale for advancing LITESPARK-011.
1L ORR 65% · Median PFS 24.0 monthsLITESPARK-011: First-Line Expansion Pivotal Trial
An ongoing phase 3 trial evaluating belzutifan plus lenvatinib versus cabozantinib monotherapy as first-line treatment for advanced ccRCC in approximately 814 patients. Updated 2024 analyses showed belzutifan plus lenvatinib demonstrated a median PFS of 21.0 months versus 14.6 months for cabozantinib (HR=0.79; 95% CI: 0.64–0.97; p=0.0142). OS data remain immature. This trial represents a pivotal study for belzutifan's potential expansion into first-line advanced ccRCC, a highly competitive setting.
PFS 21.0 vs 14.6 months · HR 0.79Progression-Free Survival & Response Rates Across LITESPARK Trials
Key efficacy metrics from belzutifan's phase 2 and phase 3 programme, derived from published clinical trial data and PatSnap Eureka literature analysis.
Median Progression-Free Survival by Trial & Setting
LITESPARK-003 triplet in 1L achieves 24.0 months median PFS; LITESPARK-011 combination shows 21.0 months vs 14.6 months for cabozantinib.
Safety Profile: Most Common Adverse Events (LITESPARK-004)
Anemia (90%), fatigue (56%), and headache (38%) were the most common adverse events in the VHL disease-associated RCC phase 2 trial.
Belzutifan Combinations: Immunotherapy, Targeted Therapy & Next-Generation IP
HIF-2α suppression reduces tumour-derived immunosuppressive signals (VEGF, TGF-β), creating a rational basis for combination with checkpoint inhibitors and targeted agents across multiple LITESPARK cohorts.
Belzutifan + Pembrolizumab + Lenvatinib (LITESPARK-011)
The phase 3 LITESPARK-011 trial evaluates belzutifan plus lenvatinib versus cabozantinib in first-line advanced ccRCC (~814 patients). Updated 2024 data show median PFS of 21.0 months versus 14.6 months for cabozantinib (HR=0.79; p=0.0142). OS data are immature. This triplet approach leverages complementary mechanisms: HIF-2α inhibition, VEGF-receptor blockade, and PD-1 checkpoint inhibition.
Belzutifan + Quavonlimab + Pembrolizumab (LITESPARK-010)
The LITESPARK-010 cohort evaluates belzutifan combined with pembrolizumab and quavonlimab (anti-CTLA-4) in first-line advanced ccRCC. This triplet immunotherapy-based approach is highlighted as a potentially differentiated strategy, combining HIF-2α inhibition with dual checkpoint blockade (anti-PD-1 and anti-CTLA-4) to maximise immune landscape modulation.
Belzutifan vs Standard of Care: Key Efficacy Comparisons
Understanding belzutifan's positioning requires benchmarking against established first-line and second-line RCC regimens tracked via PatSnap life sciences intelligence and published at NEJM.
| Trial / Regimen | Setting | ORR | Median PFS | Key Comparator | HR (PFS/OS) |
|---|---|---|---|---|---|
| LITESPARK-004 — Belzutifan monotherapy | VHL disease-associated RCC | 49% | 14.4 months | No comparator (single arm) | — |
| LITESPARK-005 — Belzutifan vs Everolimus | 2L/3L advanced ccRCC (post IO + VEGF-TKI) | 21.9% vs 3.5% | 5.6 vs 5.6 months | Everolimus | OS HR 0.88 (0.73–1.06) |
| LITESPARK-011 — Belzutifan + Lenvatinib vs Cabozantinib | 1L advanced ccRCC | — | 21.0 vs 14.6 months | Cabozantinib | PFS HR 0.79 (0.64–0.97) |
| LITESPARK-003 — Belzutifan + Len + Pembro | 1L advanced ccRCC | 65% (n=40) | 24.0 months | Phase 1b/2, no randomised comparator | — |
| CheckMate 9ER — Nivolumab + Cabozantinib | 1L advanced/metastatic RCC | 56.0% vs 27.1% | 16.6 vs 8.3 months | Sunitinib | OS HR 0.70; PFS HR 0.51 |
Track Every RCC & HIF-2α Patent Filing in Real Time
PatSnap Eureka monitors 120+ million patent documents across 120+ countries for R&D and IP teams.
Belzutifan IP Landscape: Merck's Portfolio & Emerging Competitors
Merck Sharp & Dohme Corp holds a substantial patent portfolio around belzutifan and next-generation HIF-2α inhibitors. Key filings include patents on novel HIF-2α inhibitor compounds with distinct chemical scaffolds featuring fluoroalkyl, azabicyclo, and spirocyclic motifs — providing potential differentiation in efficacy or pharmacokinetic profiles, with preclinical activity in VHL-deficient tumour xenograft models.
Merck also holds patents covering methods of treating RCC using combinations of HIF-2α inhibitors with mTOR inhibitors, demonstrating synergistic effects in ccRCC preclinical models by simultaneously blocking HIF-2α-driven angiogenesis and tumour cell proliferation pathways. This IP is directly relevant to the LITESPARK-005 context (belzutifan vs everolimus) and potential next-generation regimens. Track the full Merck IP portfolio via PatSnap's patent analytics tools.
Beyond Merck, Cambridge Enterprise Limited has filed patents on structurally distinct HIF-2α inhibitors and ARNT (HIF-1β) inhibitors. ARNT inhibitors could provide broader inhibition of HIF transcriptional activity than selective HIF-2α inhibitors like belzutifan and are positioned as potential resistance-overcoming next-generation agents. Peloton Therapeutics (acquired by Merck) also holds foundational patents covering the PAS-B domain binding mechanism. Monitor competitor filings on PatSnap's global patent database. External patent activity is also tracked by the European Patent Office.
Preclinical work establishing the HIF-2α inhibitor class showed that EPAS1 gain-of-function mutations occur in 11% (50/453) of sporadic pheochromocytoma and paraganglioma tumours — indicating potential future indications beyond RCC where HIF-2α targeted therapies may have implications. The broader hypoxia-driven disease landscape, including pulmonary arterial hypertension, is also covered in emerging patent filings.
Belzutifan HIF-2α Inhibitor Pipeline — Key Questions Answered
Belzutifan (MK-6482, Welireg) is a potent, selective, and orally available HIF-2α inhibitor developed by Merck. It acts by binding to the PAS-B domain of HIF-2α, disrupting its heterodimerization with ARNT (HIF-1β). This prevents transcriptional activation of hypoxia-response genes including VEGF, PDGF, EPO, TGF-α, GLUT1, and cyclin D1 — which are constitutively activated in VHL-deficient tumours.
The phase 2 LITESPARK-004 trial (NCT03401788) enrolled 61 patients with VHL disease-associated renal cell carcinoma. Belzutifan at 120 mg once daily demonstrated a confirmed objective response rate (ORR) of 49% and a median duration of response that had not been reached at data cutoff. The estimated probability of maintaining response at 24 months was 82%, indicating durable responses. This trial formed the basis for belzutifan's FDA approval for VHL disease-associated tumours.
LITESPARK-005 was a phase 3 randomised study evaluating belzutifan versus everolimus in 746 patients (373 per arm) with advanced ccRCC who previously received anti-PD-1/PD-L1 therapy and a VEGF-targeted agent. Belzutifan demonstrated a confirmed ORR of 21.9% versus 3.5% for everolimus (p<0.0001). Median PFS was 5.6 months for both arms. Overall survival data were immature, but the hazard ratio favoured belzutifan (HR=0.88; 95% CI: 0.73–1.06).
LITESPARK-011 is an ongoing phase 3 trial evaluating belzutifan plus lenvatinib versus cabozantinib monotherapy as first-line treatment for advanced clear cell renal cell carcinoma. The trial enrolled approximately 814 patients. Updated 2024 analyses showed belzutifan plus lenvatinib demonstrated a median PFS of 21.0 months versus 14.6 months for cabozantinib (HR=0.79; 95% CI: 0.64–0.97; p=0.0142). OS data remain immature.
The phase 1b/2 LITESPARK-003 study evaluated belzutifan in combination with lenvatinib and pembrolizumab in advanced ccRCC. The triplet combination achieved an ORR of 65% in first-line ccRCC patients (n=40) with a median PFS of 24.0 months. In previously treated patients, ORR was 48% (n=25). These results provided the rationale for advancing LITESPARK-011.
Across clinical trials, the most common adverse events with belzutifan include anemia (90% in LITESPARK-004), fatigue (56%), and headache (38%). In the LITESPARK-005 trial, anemia was the most common adverse event and was generally manageable with erythropoiesis-stimulating agent support or dose modification. The overall safety profile was consistent across trials.
Still have questions about belzutifan's pipeline? Let PatSnap Eureka answer them instantly.
Ask Eureka About BelzutifanAccelerate Your HIF-2α & RCC Pipeline Research
Join 18,000+ innovators already using PatSnap Eureka to track drug pipelines, patent landscapes, and clinical trial outcomes across oncology.
References
- Jonasch E et al. "Belzutifan for Renal Cell Carcinoma in von Hippel-Lindau Disease." NEJM, 2021.
- Choueiri TK et al. "Phase 3 LITESPARK-005 Study: Belzutifan Versus Everolimus in Previously Treated Advanced Renal Cell Carcinoma." NEJM, 2023.
- Motzer RJ et al. "Phase 3 LITESPARK-011 Trial: Belzutifan Plus Lenvatinib Versus Cabozantinib in Advanced Renal Cell Carcinoma." JCO, 2024.
- Jonasch E et al. "Belzutifan Plus Lenvatinib and Pembrolizumab in Combination for Advanced Renal Cell Carcinoma (LITESPARK-003)." JCO, 2023.
- Dhillon S. "Belzutifan: First Approval." Drugs, 2021.
- Cho H et al. "The Discovery of Belzutifan as a Potent, Selective, and Orally Available Small Molecule Inhibitor of HIF-2α." J Med Chem, 2021.
- Rini BI et al. "Belzutifan Combinations in Renal Cell Carcinoma Immunotherapy." Clin Cancer Res, 2023.
- George S et al. "Belzutifan for Advanced Renal Cell Carcinoma After Immunotherapy and Targeted Therapy: A Systematic Review." Clin Cancer Res, 2024.
- Choueiri TK et al. "First-Line Nivolumab Plus Cabozantinib Versus Sunitinib in Advanced Renal Cell Carcinoma (CheckMate 9ER)." NEJM, 2021.
- Kaelin WG. "The Molecular Biology of VHL Disease and HIF-2α Dysregulation in Oncogenesis." Cancer Cell, 2022.
- Crona J et al. "EPAS1 Gene Mutations in Sporadic Pheochromocytoma and Paraganglioma." Front Endocrinol, 2014.
- European Patent Office — patent search and IP landscape resources.
- ClinicalTrials.gov — LITESPARK trial registrations (NCT03401788, NCT02974738).
- U.S. Food & Drug Administration — Welireg (belzutifan) approval, August 13, 2021.
All data and statistics on this page are sourced from the references above and from PatSnap's proprietary innovation intelligence platform.
PatSnap Eureka searches patents and research to answer instantly.